tbuckley/cabot-search huggingface dataset:
Abstract P2-02-03: Influence of Pre-Operative MRI on the Eligibility for Accelerated Partial Breast Irradiation (APBI)
Authors: M Kühr, M Stölzle, C Leutner, S Schrading, C Kuhl, W Kuhn, M. Braun
Journal: Cancer Research (2010)

Abstract Purpose: Accelerated partial breast irradiation (APBI) following breast-conserving therapy is currently under investigation in prospective randomized studies. Multifocality and multicentricity are exclusion criteria for APBI. It is proven that pre-operative breast MRI has the ability to dectect ipsilateral and contralateral invasive tumor foci or DCIS in addition to conventional diagnostic methods (clinical examination, mammography and ultrasonography). The objective of this retrospective study was to evaluate the impact of pre-operative MRI on the patient selection for APBI. Patients and methods: From 2002 until 2007 a total of 579 consecutive, non-selected patients with newly-diagnosed early-stage breast cancer received pre-operative Breast MRI in addition to conventional imaging studies at the Bonn University Breast Cancer Center. In total, 130 patients met the criteria for APBI by conventional imaging studies (pathologic tumor size ≥3 cm, negative axillary node status, unifocal disease, no evidence of distant metastases, no invasive lobular carcinoma, lobular carcinoma in situ or Paget's disease). We analyzed the amount of additional ipsi-and contralateral tumor foci detected by MRI. Results: MRI detected additional tumor foci in 7,6 % of patients eligible for APBI (11 tumor foci in 10 out of 130 patients), either ipsilateral (n=7/5,4%) or contralateral (n=4/3.1 %). In one patient MRI found an additional tumor focus both ipsi-and contralateral. Conclusions: Pre-operative breast MRI may be useful for patient selection for APBI. Its ability to identify additional tumor foci in a clinically relevant number of cases may help to avoid undertreatment of these patients. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-02-03.
SAT0283 High Incidence of Flare After Discontinuation of Disease Modifying Anti-Rheumatic Drugs in Patients with Psoriatic Arthritis
Authors: E. G. Araujo, S. Finzel, D. A. Schreiber, A. Kleyer, M. Englbrecht, G. Schett
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In the era of modern anti-rheumatic therapy, it is now possible to contemplate the idea of clinical remission in patients with psoriatic arthritis (PsA)<sup>1</sup>. It is however unknown whether patients in clinical remission can stop methotrexate (MTX) or tumor necrosis factor inhibitor (TNFi) treatment<sup>2</sup>. <h3>Objectives</h3> To investigate drug-free remission in patients with PsA and potential predictors for flare. <h3>Methods</h3> Patients with PsA in remission (no musculoskeletal symptoms, no or minimal skin/nail disease) for at least 6 months were included. At baseline the following parameters were assessed: age, sex, BMI, disease duration, duration of remission, swollen joint count, tender joint count, VAS-pain, VAS-global, NAPSI, PASI, MASES, LDI, HAQ-DI, SF-36, FACIT-F, anti-rheumatic therapy (MTX, TNFi), ESR and CRP. In addition, ultrasound of 20 joints and 20 enthesis was performed. After discontinuation of therapy at day 1, patients were followed for 6 months for the occurrence of flares. <h3>Results</h3> 26 patients (20 males, 6 females) were enrolled. Mean ± SD age was 55 ± 14 years, mean ± SD disease duration was 6.1 ± 6.2 years, mean ± SD duration of remission was 23.9 ± 23.7 months. 15 patients received MTX monotherapy, 11 were treated with TNFi (6 in combination with MTX). We observed a high incidence of flares (76.9%, N= 20), with flares occurring relatively early (74.50 ± 50.79 days). There was no difference in flare rates between the MTX and TNFi groups. Due to our low number of patients, predictors of flare could not be determined but some important trends were observed. Male patients were more likely to flare (OR=18.00; [95%CI: 1.92-168.99]; p=0.011); patients with lower BMI (U=33.50, z=-1.61, p=0.107, r=0.32) and longer disease duration (U=35.50, z=-1.51, p=0.132, r=0.30) showed medium effect trends to flare. Further, presence of calcifications at the enthesial sites was associated with flares (U=33.50, z=-1.50, p=0.133, r=0.30). <h3>Conclusions</h3> This study showed a high incidence of flare in patients with PsA after discontinuing therapy. Although remission in PsA is an obtainable goal, drug-free remission may not be realistic for the majority of patients. Our study suggests that some baseline characteristics, such as male sex, low BMI, longer disease duration and enthesial calcifications predict flares of PsA after discontinuation of anti-rheumatic therapy. <h3>References</h3> Kavanaugh A., Fransen J., Defining remission in psoriatic arthritis. Clin Exp Rheumatol 2006: 24(Suppl. 43): S83-S87. Saber TP, et al., Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Research &amp; Therapy 2010, 12:R94. <h3>Disclosure of Interest</h3> None Declared
AB0533 Gender differences in spinal mobility reduction caused by ankylosing spondylitis in medium and long term assessed by a motion capture system.
Authors: E. Collantes-Estevez, J. L. Garrido-Castro, V. Perez-Guijo, C. Gonzalez-Navas, J. Gil-Cabezas, M. A. Garcia-Rodriguez, P. Font-Ugalde, A. M. Galisteo, R. Medina-Carnicer
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Ankylosing spondylitis (AS) is a chronic inflammatory disease which causes a reduction in the patient mobility. Several studies show that, at radiological level, structural damage is much higher in men. There are few studies about gender differences in spinal mobility. Recently new technologies as motion capture have been introduced for assessing spinal mobility[1]. <h3>Objectives</h3> To analyze, using measures obtained by a motion capture system, gender differences in spinal mobility of patients with AS in the medium and long term. <h3>Methods</h3> 70 AS patients were analized (76.7% men). Two groups of patients were defined: medium and long term according disease duration (long term &gt; 10 years). Cervical and spinal mobility were assessed using a motion capture system, the UCOTrack© [1]. Questionnaries about function and activity, conventional metrology (BASMI), and radiological scores (mSASSS) were also obtained. From motion capture several measurements were analyzed included a metrological index, the UCOASMI, based on motion capture measurements. <h3>Results</h3> No significant differences between men and women in self-rated questionnaires were found, although women obtain worse scores particularly in the medium term. Occiput-wall distance differences was found between sexes. Some measures obtained by the motion capture system were different between genders: UCOASMI, lateral spinal flexion and cervical flexion. <h3>Conclusions</h3> Results obtained by motion analysis corroborate similarities between genders as shown by several authors. Men have better mobility at medium term, inverting this difference at long term due mainly to structural damage. Motion capture provided additional accuracy information that can be useful in the diagnosis and therapeutic management of the disease. <h3>References</h3> Assessment of spinal mobility in ankylosing spondylitis using a video-based motion capture system. Garrido-Castro J.L, Medina-Carnicer R, Schiottis R., Galisteo A.M, Collantes E., Gonzalez-Navas C. Manual Therapy 2012 Oct;17(5):422-6. <h3>Disclosure of Interest</h3> None Declared
Acyclovir for the Prevention of Recurrent Herpes Simplex Virus Eye Disease
Authors: Kirk R. Wilhelmus, Roy W. Beck, Pamela S. Moke, Chandler R. Dawson, Bruce A. Barron, Dan B. Jones, Herbert E. Kaufman, Natalie Kurinij, R. Doyle Stulting, Joel Sugar, Elisabeth J. Cohen, Robert A. Hyndiuk, Penny A. Asbell
Journal: New England Journal of Medicine (1998)

Long-term treatment with antiviral agents has been shown to prevent recurrences of genital and orofacial herpes simplex virus (HSV) disease, but it is uncertain whether prophylactic treatment can prevent recurrences of ocular HSV disease.
Adapting Preclinical Concepts for Use in Clinical Trials of Serosal and Interstitial Photodynamic Therapy
Authors: Keith Cengel
Journal: Journal of the National Comprehensive Cancer Network (2012)

Photodynamic therapy (PDT) requires an optimal combination of drug and light. To achieve the ideal conditions, a tight bond between the research laboratory and the clinic is essential. This continual 2-way street allows preclinical ideas and concepts to be tested in the clinic and refinements in technique to be made. This article clearly illustrates the close connection between the bench and the bedside, exploring intraoperative pleural PDT, challenges in matching fluence and photosensitizer, improvements in animal models that lead to adjustments in the operating room, and clinical applications for interstitial PDT in prostate cancer and beyond.
SP0054 Mirna in rheumatoid arthritis epigenetics
Authors: A. Jüngel
Journal: Annals of the Rheumatic Diseases (2013)

MicroRNAs (miRNAs) are a class of endogenous, highly conserved, small, non-coding RNAs that regulate gene expression at the post transcriptional level, and can act as key regulators of cellular mechanisms. Over the past years, dysregulation, malfunction or mutations of miRNAs have been described to be functionally involved in cancer as well as inmany other diseases. Therefore, the potential role of miRNAs linked with epigenetic modifications in the pathogenesis of autoimmune diseases such as rheumatoid arthritis (RA) is raising great expectations. In the last years more and more publications have appeared showing that patients with RA are characterized by alterations in the expression of miRNAs. In this lecture we will focus on differentially expressed miRs in cells (peripheral blood cells such as T cells, synovial tissue, synovial fibroblasts) and body-fluids (sera and synovial fluid) of patients with RA. Based on the human TNF transgenic mouse model we will show how we could discover novel miRs (miR-221 and -223) associated with the pathogenesis of RA. Since one miR can regulate hundreds of genes we will explore the main function of specific miRs (miR-155) considering their phenotype in knock-out animals. Further, we will discuss how we can link the lack (miR-124 or -196) or over-expression (miR-155, -203) of miRs to inflammatory and immune processes in RA. Based on the fact that miRs are localized in microvesicles, bound to Argonaute proteins and/or high density lipoproteins (HDL) surprisingly miRs are of high stability in body fluids such as sera or synovial fluids and could serve as potential biomarkers. Finally we will discuss novel strategies to target miRs in the treatment of RA. <h3>Disclosure of Interest</h3> None Declared
P354 CHOLANGIOCYTES FROM PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS EXPRESS CD1D AND HUMAN CHOLANGIOCYTES PRESENT ANTIGENS TO NATURAL KILLER T CELLS
Authors: E. Schrumpf, C. Tan, T.H. Karlsen, J. Sponheim, D.M. Jefferson, S. Zeissig, M.A. Exley, R.S. Blumberg, E. Melum
Journal: Journal of Hepatology (2014)
Effect of Mannitol on the Kidney
Authors: William M. Stahl
Journal: New England Journal of Medicine (1965)

THE use of hypertonic mannitol as an osmotic diuretic has captured the attention and imagination of investigators and clinicians alike in the past several years. First used widely by physiologists to promote urine flow during studies of general renal physiology, it was reported in 1945 by Selkurt1 to improve renal function in a dog's kidney after a period of ischemia. This study led to the use of mannitol in clinical situations involving a decrease in renal blood flow or the presence of circulating nephrotoxic substances.2,3 The result of this interest has led to significant investigation of the renal, as . . .
Twenty-one States Operate Cancer Pain Initiatives
Authors: J. A. Steele
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Twenty-one States Operate Cancer Pain Initiatives Get access Julie A. Steele Julie A. Steele Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 22, 20 November 1991, Page 1613, https://doi.org/10.1093/jnci/83.22.1613 Published: 20 November 1991
Characterization of CD8+CD57+ T cells in patients with acute myocardial infarction
Authors: Hee Tae Yu, Jong-Chan Youn, Jino Lee, Seunghyun Park, Ho-Seok Chi, Jungsul Lee, Chulhee Choi, Sungha Park, Donghoon Choi, Jong-Won Ha, Eui-Cheol Shin
Journal: Cellular and Molecular Immunology (2014)
PROTESIS METALICA CUBIERTA EN LA HEMORRAGIA POST-ESFINTEROTOMÍA ENDOSCÓPICA O PARA PREVENIRLA EN PACIENTES DE ALTO RIESGO
Authors: M Masachs Peracaula, J Dot Bach, M Abu-suboh Abadia, J Armengol Bertrolí, A Benages Curell, JC Salord Oses, SV Kantsevoy, JR Armengol-Miró
Journal: Endoscopy (2011)

Introducción: Un efecto adverso en la terapéutica de la esfinterotomía biliar endoscópica es la hemorragia immediata o tardía. Describimos una nueva técnica hemostática utilizando una prótesis metálica autoexpandible cubierta para la hemorragia post-ERCP o para prevenirla en pacientes con alto riesgo. Factores de riesgo son la coagulopatía, anticoagulación inferior a 3días después de la ERCP, colangitis previa a la ERCP, sangrado durante la ERCP. Otros factores de riesgo podrían ser un colédoco dilatado, litiasis en colédoco, divertículo peripapilar, precut.
Abstract LB-353: From worms to humans: understanding the role of microRNAs in cancer progression
Authors: Aurora Esquela-Kerscher
Journal: Cancer Research (2010)

Abstract MicroRNAs (miRNAs) regulate important developmental events and are often misexpressed in human cancers, but little is known regarding how these small RNAs contribute to tumor formation. Our laboratory uses a combination of nematode and mammalian model systems to functionally characterize miRNAs and determine the role these factors play in controlling cancer progression pathways. We have successfully used the nematode to analyze how members of the lin-4 and let-7 miRNA families functionally overlap to direct common developmental events associated with cell cycle progression and differentiation. Specifically, animals that carry a triple deletion for the lin-4 homologue, mir-237, and the let-7 homologues, mir-48 and mir-84, exhibit morphological defects and fertility problems related to abnormal mitotic and meiotic abnormalities in the germline that were not found in the single or double deletion combinations. We have also begun to determine how the let-7 miRNA family functions as tumor suppressor genes in mammals. Our experiments showing that exogenous let-7 miRNA administration in the lung using a conditionally activated KRAS lung cancer mouse model result in reduced lung tumor load in these animals highlight the therapeutic potential of miRNAs. We are also studying the role of let-7 together with other miRNA families in directing cancer progression pathways in human tissues of urothelial origin. For instance, we find that let-7 is dysregulated in human prostate cancer cell lines differing in their metastatic status and indicates a novel role for this miRNA in prostate cancer progression. Due to our access to a vast repository of human prostate specimens from the Virginia Prostate Center at Eastern Virginia Medical School, we have begun to analyze the miRNA expression profiles in FFPE specimens taken from the primary prostate tumor, normal adjacent tissue and the lymph node metastasis of individual prostate cancer patients as well as in tumors from patients presenting insignificant and organ confined cancer. We are also determining the “miRNA signatures” in blood, urine, and expressed prostatic secretions (EPS) that were obtained non-invasively from both normal and cancer patients. Our work investigating the role of miRNAs during cancer progression promises to reveal novel therapeutic approaches and diagnostic and prognostic biomarkers for human cancer. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-353.
Commentary: Human Cancer Risk from Ingested Asbestos: A Problem of Uncertainty
Authors: William J. Nicholson
Journal: Environmental Health Perspectives (1983)

EffectsAlthough studies of populations exposed to high concentrations of asbestos fibers in drinking water appear attractive as research opportunities to define an asbestos-related risk, they are un- likely to provide a definitive answer to the question of whether asbestos in drinking water is associated with an elevated risk of malignancy.Consider, for example, a hypothetical 10-yr anal- ysis of the deaths in a city of 1 million persons whose water supply is contaminated with 100 million fibers per liter (f/L) (a gross overestimate of any real situation).From the estimates in the asbestos criteria document (1), ingestion of this water over a 70-yr period would give rise to an added risk of death 3.3 x 10-3 per person.Tb estimate the number of asbestos-related deaths in this population, using the above risk data, assume that the average residence time of those deceased in the contaminated area is 14 yr and that the distribution of residence times follows an exponential function, exp {t/14}.This distribution will certainly overestimate residence times compared with actual populations.Nearly half the census tracts in the U.S. EPA-sponsored San Francisco study, for example, showed more than 53% of the residents moving within 5 yr (2).Assume also that 7 yr is required for the risk of asbestos malignancy to manifest itself, as is the case for lung cancer.(See Fig. 1 for the expression of the relative risk of lung cancer in insulators.)This would appear to be so for gastrointestinal cancer (Fig. 2), but will lead to significant overes- timates of risk for peritoneal mesothelioma be- cause most such tumors do not appear until after 30 yr or more from first exposure.Approximately
FRI0336 Comparison of construct validity of two functional ability measures in children with juvenile dermatomyositis:
Authors: C. Ferrari, A. Consolaro, G. Varnier, A.P. Rao, D. Lazarevic, E. Demirkaya, J.K. Kadel, A. Civino, N. Ruperto, A. Martini, A. Ravelli
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Physical function in children with juvenile dermatomyositis (JDM) is traditionally assessed through the Childhood Health Assessment Questionnaire (CHAQ), which has been originally devised for juvenile idiopathic arthritis, but has been validated for use in JDM. Recently, the first physical functional questionnaire specific for JDM, named MyoFun, has been developed. The MyoFun is a 15-item questionnaire in which the ability of the child to perform each task is scored as follows: 0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; 3 = unable to do. Questionnaire completers are asked to note only those difficulties that are caused by myositis. The total score ranges from 0 to 45. <h3>Objectives</h3> To compare the construct validity of the CHAQ and MyoFun in children with JDM. <h3>Methods</h3> Construct validity of the CHAQ and Myofun was assessed by evaluating their Spearman's correlation with the other traditional JDM outcome measures. Construct validity of the CHAQ and MyoFun was assessed in 3 different cross-sectional patient samples. The first and second samples, in which physical function was assessed with the CHAQ, included 327 patients enrolled in a long-term outcome study (Arthritis Care Res 2010;62:63-72) and 294 patients evaluated at disease onset or at the time of a disease flare (Arthritis Rheum 2008;59:4-13), respectively. The third sample, in which physical function was assessed with the MyoFun, was composed by 37 patients seen at study centers in the context of standard clinical care. <h3>Results</h3> Table shows Spearman's correlations yielded by the CHAQ and MyoFun. <h3>Conclusions</h3> The construct validity of the MyoFun was overall superior to that of the CHAQ, which suggests that this tool is suitable for the assessment of physical function in children with JDM in both clinical practice and research. <h3>Disclosure of Interest</h3> None Declared
Frequent allelic loss of the RB, D13S319 and D13S25 locus in myeloid malignancies with deletion/translocation at 13q14 of chromosome 13, but not in lymphoid malignancies
Authors: K Tanaka, M Arif, M Eguchi, SX Guo, Y Hayashi, H Asaoku, T Kyo, H Dohy, N Kamada
Journal: Leukemia (1999)
P673 DETECTION AND DERIVATION RATE AFTER PEER-TO-PEER TRAINING SESSIONS IN PRIMARY CARE ON THE SCREENING OF HEPATITIS B
Authors: M.Á. Otero-Fernández, R. Llorca, J. Ampuero, A. Martinez-Alcala, M. Vargas-Perez, J. Vargas-Romero, M. Cortes, M. Romero-Gomez
Journal: Journal of Hepatology (2014)
Bone effects of exemestane vs. tamoxifen within the TEAM trial: results of a prospective randomized bone sub study.
Authors: P Hadji, M Ziller, D Kieback, W Dornoff, HW Tessen, J Kuck, A Hasenburg
Journal: Cancer Research (2009)

Abstract Abstract #1143 Background: A prospective open label randomized multicenter trial was performed in the German TEAM Trial Group to compare the effects of the steroidal aromatase inhibitor Exemestane (EXE) and the ER agonist/antagonist Tamoxifen (TAM) on bone mineral density (BMD) and markers of bone turnover during adjuvant treatment of postmenopausal women with estrogen receptor positive breast cancer.&amp;#x2028; Methods: 200 postmenopausal estrogen receptor positive breast cancer women&amp;#x2028; were included in the bone substudy. Women with a history of osteoporosis or a disease or treatment known to effect bone metabolism were excluded. BMD and markers of bone turnover were assessed at baseline, after 6 and 12 months of treatment. BMD was performed using dual x-ray absorptiometry (DXA) at the lumber spine and femoral neck (FN). Marker of bone formation, PINP, bone specific alkaline phosphatase (BAP) and osteocalcin (OC) as well as bone resorption marker (ICPM) were analysed using standardised methods. Intent-to-treat analysis was performed based on 200 patients. The primary endpoint was to compare Exemestane and Tamoxifen with regard to changes from baseline to month 12 in BMD (g/cm²) in lumbar spine (integral of L1-L4). Results: 156 patients with a mean age of 61 yr. (+/- 7.3 yr.) were available for final analysis. Both groups were comparable regarding age, height, tumor grade and stage. Compared to women on Tamoxifen, who comprised an BMD increase of +0.9% and +0.9% after 6 and 12 months at the spine, women on EXE showed a decrease of -2.8% and -3.6%. Conversely, BMD at the FN showed a decrease of -2.1% and -2.2% in women on TAM while women on EXE showed a decrease of -3.4% after 6 and an increase of +1.1% after 12 months, respectivly. Bone formation and absorption was modulated in both groups. Details will be presented at the meeting.Conclusion: The results of the 12 months analysis in the TEAM Bone substudy confirm the bone protective effect of TAM at the spine while conversely the results at the FN showed a decrease. Women on EXE showed a decrease at the spine while there was a neutral effect at the FN. Futher evaluation of the 24 months data as well as the fracture rate of the total TEAM trial are nessecary to evaluate the effect of EXE on bone health. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1143.